Key Team Members
Founder and CEO
Mr. Lawrence Forman has 37 years’ experience in academic and industrial biological and biotechnology research and in cell culture process development and related areas. Mr. Forman has held positions at the Albert Einstein College of Medicine, Genentech (1980-1996), CuraGen, and Applikon Biotechnology. Mr. Forman has worked as a consultant for numerous biopharma clients and has experience in cell culture process and medium development; online process monitoring and control; cell banking; GMP manufacturing; on- and off-line analytical development; virus inactivation; process engineering. Mr. Forman received a B.A. in Biology from the State University of New York—New Paltz.
Co-Founder and Chief Scientific Advisor
Dr. Lawrence Chasin is a Professor of Biological Sciences at Columbia University. Professor Chasin’s research is aimed at discovering the sequence signals in DNA that control the expression of Human genes. His earliest major contribution was to help found the field of mammalian cell genetics where he demonstrated that genetic manipulation could succeed in mammalian cells just as it had in microorganisms. Professor Chasin’s seminal works led to new fields of study: “gene amplification” and “nonsense-mediated decay.” Prof. Chasin has consistently pushed the development and use of new technologies. This includes the creation of Chinese Hamster Ovary host cell lines produced by Prof. Chasin’s laboratory that are now the gold standard for the commercial production of therapeutic monoclonal antibodies and are used by nearly all biopharmaceutical companies worldwide for research on, and/or the production of, a majority of licensed human protein therapeutic products.
Director of Cell Engineering
Yale University, Stanford University, UCSF;
15 years cell and molecular biology, cancer cell genetics;
Lawrence Berkeley National Laboratory, Bell Biosystems
Business Development Advisor
Karen is the Managing Director of the QB3 Executive Mentorship pilot program for life science and medical technology entrepreneurs emerging from all ten University of California campuses. Previously, Karen was the CEO of Redwood Bioscience which she joined as the first non-founder employee in 2009, leading the company through its successful acquisition by Catalent (CTLT) in 2014. Redwood, now Catalent Biologics West, continues to be a pioneer in developing therapeutic conjugate technology and antibody-drug conjugates for improving cancer treatment. Prior to joining Redwood, Karen co-founded and was a Partner with Thomas, McNerney & Partners ("TMP"), a med tech-focused venture firm with $600 million under management. She co-founded TMP with a partner at Coral Ventures, where she had been a General Partner and a colleague at Warburg Pincus LLC, where she had been a member of the health care technology venture group. During her venture career, Karen was involved with 15 companies from initial investment that went public and/or were acquired; three of which she launched in collaboration with their scientific founders. Karen began her career as a member of Alex. Brown & Sons’s health care and insurance corporate finance teams. She graduated Phi Beta Kappa and magna cum laude with a B.S. In Economics from the Wharton School at the University of Pennsylvania.
Mr. Bronstein was the former CEO of Brevity Ventures which acquired by AllDigital 2014. Mr. Bronstein has spent the past 15 years building companies and corporate departments in the SaaS, Enterprise Hardware and Consumer Products spaces. Working alongside pioneers in the fields of computer science and neuroscience on human language and speech.